Participants in this study will be patients who have a cardiac resynchronization device implanted in their heart, which helps coordinate the heart’s pumping action. These patients must have shown exceptional improvement with this device, having a heart pumping function that has recovered to normal levels and no signs of scarring on special heart imaging tests. They must also have had genetic testing that did not show any inherited heart disease genes. The study will compare two groups: one group will gradually stop taking their heart medications under medical supervision, while the other group will continue taking their medications as usual.

During the study, patients will be monitored for nine months with regular check-ups that include heart function tests using ultrasound, blood tests to measure heart stress markers, quality of life assessments, and device checks to monitor heart rhythm. The main focus will be on whether stopping the medications leads to a worsening of heart function or return of heart failure symptoms within six months. Additional monitoring will continue for twelve months to track emergency visits, hospital admissions, heart rhythm problems, and overall well-being. The study will use various imaging techniques and blood tests to carefully assess heart function throughout the treatment period.

The purpose of the study is to see if ninerafaxstat can improve health status in people with symptomatic non-obstructive hypertrophic cardiomyopathy. The study will look at how the medication affects symptoms and quality of life, as well as how well people can exercise. The treatment will be given over a period of 12 weeks, with the highest daily dose being 400 milligrams and a total maximum dose of 33,600 milligrams over the entire treatment period.

During the study, participants will undergo various assessments including heart ultrasound examinations, which use sound waves to create pictures of the heart, and exercise tests where breathing and heart function are measured while exercising. The study will track changes in symptoms and how they affect daily activities by using questionnaires that ask about physical limitations, symptoms, quality of life, and overall health. Neither the participants nor the doctors will know who is receiving the actual medication and who is receiving the placebo during the study.

The purpose of this study is to compare how well gadopiclenol works compared to gadoterate meglumine in producing clear images of the heart in children during MRI scans. The study will look at the quality of the images and how well doctors can see important details of the heart, including areas where the heart muscle may be damaged or scarred, which is called myocardial fibrosis. During the study, children will receive an injection of gadopiclenol during their MRI scan, and the images will be compared to previous scans that were done using gadoterate meglumine within the past year or two.

Children participating in this study will be between two and eighteen years old and will need to have a heart MRI scan as part of their regular medical care. The study will involve one MRI scan using gadopiclenol, and doctors will compare these new images with older images from a previous scan that used gadoterate meglumine. Some children may need to be sedated, which means they will be given medication to help them stay calm and still during the scan. The study will also monitor for any unwanted effects or problems that might occur after receiving the contrast agent.

The purpose of the study is to find out if giving this stem cell treatment through an infusion into the vein can help restore heart function in people who have been recently diagnosed with this type of heart failure. The study will compare how well the heart works in patients who receive the stem cell treatment versus those who receive the placebo. Patients in the study will receive their assigned treatment through infusions and will be followed for twelve months to see how their heart function changes over time.

During the study, doctors will measure various aspects of heart function using different methods. They will check the heart’s pumping ability and the size of the heart chambers at different time points after the treatment. Doctors will also assess how patients feel and function in their daily lives by checking their symptoms, their ability to walk for six minutes, and asking them to complete questionnaires about their quality of life. Blood tests will be performed to measure a substance that indicates heart stress. The study will also carefully monitor any unwanted effects or reactions that patients may experience to ensure the treatment is safe.

The medication Nucresiran is given as an injection using a pre-filled syringe. The study aims to evaluate how well this new treatment works in patients who have heart problems related to protein buildup in their heart tissue. Some participants will receive the study medication, while others will receive a placebo.

During the study, doctors will monitor patients’ heart health and track any heart-related hospitalizations or urgent care visits. The study will also look at how the treatment affects patients’ quality of life and overall survival. Patients may continue taking their regular heart failure medications and other approved treatments for their condition while participating in the study.

The purpose of the study is to see if this treatment can help improve heart function in patients with this condition, for which there are currently no effective treatments. Participants in the study will receive either the cell treatment or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving the actual treatment or the placebo, to ensure unbiased results.

Throughout the study, participants will undergo various assessments to monitor changes in their heart function and overall health. These assessments include clinical evaluations, heart imaging tests, and exercise tests. The study aims to determine if the treatment can lead to better heart function and fewer heart-related problems over time. Participants will be closely monitored with regular check-ups and follow-ups to ensure their safety and to gather comprehensive data on the treatment’s effectiveness.

The purpose of this study is to explore how Entresto can help prevent the progression of ARVC by examining its effects on heart muscle changes and heart function. Participants in the study will be randomly assigned to receive either the medication or a placebo. The study will last for a period of up to 48 weeks, during which participants will take the medication orally in the form of film-coated tablets. Throughout the study, various tests such as Cardiac Magnetic Resonance (CMR) and Electrocardiogram (ECG) will be conducted to monitor heart health and function.

By participating in this study, researchers aim to gather valuable information on how Entresto can potentially benefit individuals with ARVC. The study will focus on assessing changes in heart muscle structure, heart function, and the occurrence of irregular heartbeats. This research could contribute to better understanding and management of ARVC, potentially leading to improved treatment options for those affected by this heart condition.

The purpose of the study is to see if dapagliflozin can help prevent heart problems that might occur as a side effect of the chemotherapy. Participants in the study will be randomly assigned to receive either dapagliflozin or the placebo. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are not biased. The study will last for 12 months, during which time the participants’ heart health will be monitored to check for any signs of heart dysfunction, such as changes in heart function or structure, or changes in certain heart-related biomarkers.

Throughout the study, the participants’ heart health will be assessed at different points, including at 6 and 12 months, to see if there are any changes in heart function or symptoms of heart failure. The study will also look at other health outcomes, such as changes in quality of life and any side effects that may occur. The goal is to determine if dapagliflozin can effectively reduce the risk of heart problems in breast cancer patients undergoing anthracycline-based chemotherapy.

Participants in the study will take the OMT-28 capsule for a period of 12 weeks. During this time, researchers will monitor the patients to see if there is a significant improvement in their condition, specifically looking for a decrease in a marker called GDF-15, which is related to inflammation. The study will also keep track of any side effects or changes in health that might occur while taking the treatment.

The trial aims to gather important information about how OMT-28 works in people with Primary Mitochondrial Disease and whether it can help reduce symptoms associated with muscle and heart problems. This research is an important step in finding new ways to manage and treat this condition.

The purpose of the study is to assess whether the treatment can lead to an improvement in heart function over a period of 12 months. Participants in the study will receive either the active medications or a placebo, and their heart function will be monitored using MRI scans. The study will track changes in heart function and other health outcomes over time to see if the treatment provides any benefits.

Participants will be randomly assigned to receive either the active treatment or a placebo, and neither the participants nor the researchers will know which treatment is being given. This is known as a double-blind study. The trial will last for up to 12 months, during which participants will have regular check-ups and tests to monitor their heart health and overall well-being. The results of this study could help improve treatment options for people with this type of heart condition.

Participants in the study will be randomly assigned to receive either colchicine or a placebo, which is a tablet that looks like the medication but does not contain the active ingredient. The study is designed to be single-blinded, meaning that the participants will not know whether they are receiving colchicine or the placebo. The treatment will be taken orally in the form of a tablet. Throughout the study, participants will be monitored for any changes in their heart condition, including improvements or worsening of symptoms.

The main goal of the study is to see if colchicine can help reduce inflammation and improve heart function in patients with inflammatory cardiomyopathy. The researchers will look at various health indicators, such as heart imaging results and the frequency of irregular heartbeats, to assess the effectiveness of the treatment. The study will also track any side effects or adverse reactions to the medication. By the end of the study, the researchers hope to gather valuable information about the potential benefits of colchicine for patients with this heart condition.